Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have recently shown that transient expression of
10-formyltetrahydrofolate dehydrogenase
(
FDH
) strongly inhibits proliferation of several cancer cell lines and ultimately results in cell death. In the present studies using Tet-On system, we have generated a stable A549 lung carcinoma cell line capable of inducible
FDH
expression. Using this system, we were able to express
FDH
at different levels depending on concentration of the inducer, doxycycline, and we have observed that inhibition of proliferation depends on
FDH
intracellular levels. We have further shown that induction of
FDH
expression results in initiation of apoptosis beginning 24 h post-induction. Apoptotic cells revealed cleavage of poly-(ADP-ribose) polymerase and general caspase inhibitor zVAD-fmk protected cells against
FDH
-induced apoptosis.
FDH
-expressing cells showed accumulation of cells in G(0)-G(1) phase and a sharp decrease of cells in S phase. Accumulation of intracellular
FDH
was followed by accumulation of the
tumor suppressor protein p53
and its downstream target p21. These results indicate that
FDH
antiproliferative effects on A549 cells include both G(1) cell cycle arrest and caspase-dependent apoptosis.
...
PMID:Ectopic expression of 10-formyltetrahydrofolate dehydrogenase in A549 cells induces G1 cell cycle arrest and apoptosis. 1280 5
A folate enzyme, FDH (
10-formyltetrahydrofolate dehydrogenase
;
EC 1.5.1.6
), is not a typical tumour suppressor, but it has two basic characteristics of one, i.e. it is down-regulated in tumours and its expression is selectively cytotoxic to cancer cells. We have recently shown that ectopic expression of FDH in A549 lung cancer cells induces G1 arrest and apoptosis that was accompanied by elevation of
p53
and its downstream target, p21. It was not known, however, whether FDH-induced apoptosis is
p53
-dependent or not. In the present study, we report that FDH-induced suppressor effects are strictly
p53
-dependent in A549 cells. Both knockdown of
p53
using an RNAi (RNA interference) approach and disabling of
p53
function by dominant-negative inhibition with R175H mutant p53 prevented FDH-induced cytotoxicity in these cells. Ablation of the FDH-suppressor effect is associated with an inability to activate apoptosis in the absence of functional
p53
. We have also shown that FDH elevation results in
p53
phosphorylation at Ser-6 and Ser-20 in the
p53
transactivation domain, and Ser-392 in the C-terminal domain, but only Ser-6 is strictly required to mediate FDH effects. Also, translocation of
p53
to the nuclei and expression of the pro-apoptotic protein PUMA (Bcl2 binding component 3) was observed after induction of FDH expression. Elevation of FDH in
p53
functional HCT116 cells induced strong growth inhibition, while growth of
p53
-deficient HCT116 cells was unaffected. This implies that activation of
p53
-dependent pathways is a general downstream mechanism in response to induction of FDH expression in
p53
functional cancer cells.
...
PMID:Cancer cells activate p53 in response to 10-formyltetrahydrofolate dehydrogenase expression. 1601 5
FDH (
10-formyltetrahydrofolate dehydrogenase
) is strongly downregulated in tumors while its elevation suppresses proliferation of cancer cells and induces
p53
-dependent apoptosis. We have previously shown that FDH induces phosphorylation of
p53
at Ser6, which is a required step in the activation of apoptosis. In the present study, we report that FDH-induced
p53
phosphorylation is carried out by JNK1 and JNK2 (c-Jun N-terminal kinases) working in concert. We have demonstrated that FDH induces phosphorylation of JNK1 and JNK2, while treatment of FDH-expressing cells with JNK inhibitor SP600125, as well as knockdown of JNK1 or JNK2 by siRNA, prevents phosphorylation of
p53
at Ser6 and protects cells from apoptosis. Interestingly, the knockdown of JNK1 abolished phosphorylation of JNK2 in response to FDH, while knockdown of JNK2 did not prevent JNK1 phosphorylation. Pull-down assay with the
p53
-specific antibody has shown that JNK2, but not JNK1, is physically associated with
p53
. Our studies revealed a novel mechanism in which phosphorylation of JNK2 is mediated by JNK1 before phosphorylation of
p53
, and then
p53
is directly phosphorylated by JNK2 at Ser6.
...
PMID:Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway. 1752 47
The folate enzyme, FDH (
10-formyltetrahydrofolate dehydrogenase
, ALDH1L1), a metabolic regulator of proliferation, activates
p53
-dependent G1 arrest and apoptosis in A549 cells. In the present study, we have demonstrated that FDH-induced apoptosis is abrogated upon siRNA knockdown of the
p53
downstream target PUMA. Conversely, siRNA knockdown of p21 eliminated FDH-dependent G1 arrest and resulted in an early apoptosis onset. The acceleration of FDH-dependent apoptosis was even more profound in another cell line, HCT116, in which the p21 gene was silenced through homologous recombination (p21(-/-) cells). In contrast to A549 cells, FDH caused G2 instead of G1 arrest in HCT116 p21(+/+) cells; such an arrest was not seen in p21-deficient (HCT116 p21(-/-)) cells. In agreement with the cell cycle regulatory function of p21, its strong accumulation in nuclei was seen upon FDH expression. Interestingly, our study did not reveal DNA damage upon FDH elevation in either cell line, as judged by comet assay and the evaluation of histone H2AX phosphorylation. In both A549 and HCT116 cell lines, FDH induced a strong decrease in the intracellular ATP pool (2-fold and 30-fold, respectively), an indication of a decrease in de novo purine biosynthesis as we previously reported. The underlying mechanism for the drop in ATP was the strong decrease in intracellular 10-formyltetrahydrofolate, a substrate in two reactions of the de novo purine pathway. Overall, we have demonstrated that p21 can activate G1 or G2 arrest in the absence of DNA damage as a response to metabolite deprivation. In the case of FDH-related metabolic alterations, this response delays apoptosis but is not sufficient to prevent cell death.
...
PMID:Activation of p21-Dependent G1/G2 Arrest in the Absence of DNA Damage as an Antiapoptotic Response to Metabolic Stress. 2259 1